YMAB Stock - Y-mAbs Therapeutics, Inc.
Unlock GoAI Insights for YMAB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $87.69M | $84.82M | $65.27M | $34.90M | $20.75M |
| Gross Profit | $72.43M | $73.40M | $57.70M | $32.38M | $18.55M |
| Gross Margin | 82.6% | 86.5% | 88.4% | 92.8% | 89.4% |
| Operating Income | $-31,201,000 | $-25,672,000 | $-94,811,000 | $-115,433,000 | $-119,935,000 |
| Net Income | $-29,666,000 | $-21,427,000 | $-95,568,000 | $-55,275,000 | $-119,337,000 |
| Net Margin | -33.8% | -25.3% | -146.4% | -158.4% | -575.1% |
| EPS | $-0.67 | $-0.49 | $-2.20 | $-1.28 | $-2.97 |
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 22nd 2025 | BofA Securities | Downgrade | Underperform | $3 |
| November 18th 2024 | Oppenheimer | Initiation | Outperform | $23 |
| August 16th 2024 | Cantor Fitzgerald | Initiation | Overweight | $20 |
| June 28th 2024 | Truist | Initiation | Buy | $21 |
| May 10th 2023 | Wedbush | Upgrade | Outperform | $13← $5 |
| April 3rd 2023 | Guggenheim | Downgrade | Neutral | - |
| January 27th 2023 | Morgan Stanley | Downgrade | Underweight | $4 |
| January 5th 2023 | Cowen | Downgrade | Market Perform | - |
| December 2nd 2022 | BofA Securities | Downgrade | Neutral | $5← $23 |
| October 31st 2022 | Wedbush | Downgrade | Neutral | $6 |
| October 31st 2022 | JP Morgan | Downgrade | Underweight | $7← $16 |
| July 6th 2022 | Canaccord Genuity | Resumed | Buy | $35 |
| June 24th 2022 | BMO Capital Markets | Initiation | Outperform | $27 |
Earnings History & Surprises
YMABEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 8, 2025 | $-0.27 | $-0.07 | +74.1% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.22 | $-0.12 | +45.5% | ✓ BEAT |
Q1 2025 | Mar 4, 2025 | $-0.13 | $-0.15 | -15.4% | ✗ MISS |
Q4 2024 | Nov 8, 2024 | $-0.16 | $-0.16 | 0.0% | = MET |
Q3 2024 | Aug 12, 2024 | $-0.13 | $-0.21 | -61.5% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $-0.20 | $-0.02 | +90.0% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.19 | $-0.18 | +5.3% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.24 | $-0.14 | +41.7% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.32 | $-0.15 | +53.1% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-0.46 | $0.03 | +106.5% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.71 | $-0.63 | +11.3% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.67 | $-0.94 | -40.3% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.72 | $-0.64 | +11.1% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.70 | $-0.85 | -21.4% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.60 | $-0.66 | -10.0% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.67 | $-0.53 | +20.9% | ✓ BEAT |
Q2 2021 | May 6, 2021 | $0.61 | $0.75 | +23.0% | ✓ BEAT |
Q1 2021 | Feb 25, 2021 | $-0.51 | $-0.48 | +5.9% | ✓ BEAT |
Q4 2020 | Nov 5, 2020 | $-0.78 | $-0.82 | -5.1% | ✗ MISS |
Frequently Asked Questions about YMAB
What is YMAB's current stock price?
What is the analyst price target for YMAB?
What sector is Y-mAbs Therapeutics, Inc. in?
What is YMAB's market cap?
Does YMAB pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to YMAB for comparison